Orthocell reported record financial results for the fourth quarter of FY24 and the full fiscal year.

Quarterly revenues reached $1.8 million, up 14.41% from the third quarter of FY24 and 9% from the fourth quarter of FY23. Annual revenue for FY24 was $6.7 million, a 30.40% increase from the previous year.

Managing Director Paul Anderson highlighted strong performance driven by flagship products Striate+ and Remplir, expanding in key markets including the US, Europe/UK, Australia, and New Zealand.

Orthocell maintains $20.6 million in cash, supporting ongoing growth initiatives in regulatory approvals and market expansion.